Literature DB >> 18622271

Expanding the evidence base in transplantation: the complementary roles of randomized controlled trials and outcomes research.

Steven K Takemoto1, Wolfgang Arns, Suphamai Bunnapradist, Louis P Garrison, Lluis Guirado, Zoltan Kalo, Gabriel Oniscu, Gerhard Opelz, Maria Piera Scolari, Sergio Stefoni, Magdi Yaqoob, Daniel C Brennan.   

Abstract

Transplantation offers a unique opportunity to demonstrate the complementary roles of randomized controlled trials and outcome research. The surgery and collaboration necessary for the transplant procedure makes randomization and blinding difficult. Because essentially every recipient is included in a transplant registry, sampling bias is minimized. Regulatory agencies generally do not consider outcomes research when assessing efficacy of new drugs or medical interventions. This workgroup summary examines the suitability of outcomes research to complement results of randomized controlled trials and related issues: efficacy versus effectiveness, internal versus external validity, data types, limitations, and analysis methodologies. Many advances in outcomes research have been pioneered in transplantation. A case is made for regulatory and reimbursement authorities to use outcomes research when making efficacy, effectiveness, and coverage decisions in transplantation.

Mesh:

Year:  2008        PMID: 18622271     DOI: 10.1097/TP.0b013e31817d4df5

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  2 in total

1.  Peritonitis in the patient on peritoneal dialysis: does the composition of the dialysis fluid make a difference?

Authors:  Danica Lam; Joanne M Bargman
Journal:  Clin J Am Soc Nephrol       Date:  2013-08-15       Impact factor: 8.237

2.  Cyclosporine versus tacrolimus: cost-effectiveness analysis for renal transplantation in Brazil.

Authors:  Augusto Afonso Guerra Júnior; Grazielle Dias Silva; Eli Iola Gurgel Andrade; Mariângela Leal Cherchiglia; Juliana de Oliveira Costa; Alessandra Maciel Almeida; Francisco de Assis Acurcio
Journal:  Rev Saude Publica       Date:  2015-02-27       Impact factor: 2.106

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.